• UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase3 ACHIEVEI and ACHIEVEII studies.
  • CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults.
  • Migraine affects an estimated 5million Canadians with the highest prevalence in women and individuals in their 30s and 40s.

MONTREAL, Aug. 4, 2026 /CNW/ -- AbbVie (NYSE:ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with moderate to severe pain.